1. Home
  2. FTW vs ARMP Comparison

FTW vs ARMP Comparison

Compare FTW & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FTW

EQV Ventures Acquisition Corp. Class A Ordinary Shares

N/A

Current Price

$10.35

Market Cap

470.2M

Sector

Energy

ML Signal

N/A

ARMP

Armata Pharmaceuticals Inc.

HOLD

Current Price

$12.28

Market Cap

383.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTW
ARMP
Founded
2017
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
470.2M
383.7M
IPO Year
2024
1996

Fundamental Metrics

Financial Performance
Metric
FTW
ARMP
Price
$10.35
$12.28
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$15.00
AVG Volume (30 Days)
106.3K
37.7K
Earning Date
N/A
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.50
$1.11
52 Week High
$17.20
$13.75

Technical Indicators

Market Signals
Indicator
FTW
ARMP
Relative Strength Index (RSI) 39.73 61.86
Support Level $9.50 $5.14
Resistance Level $10.57 $12.11
Average True Range (ATR) 0.62 1.16
MACD -0.15 0.24
Stochastic Oscillator 11.49 87.14

Price Performance

Historical Comparison
FTW
ARMP

About FTW EQV Ventures Acquisition Corp. Class A Ordinary Shares

EQV Ventures Acquisition Corp is a blank check company.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Share on Social Networks: